Insulin

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, about situations in which an ultra-long-acting insulin may be a good choice.

Adults using semaglutide for type 2 diabetes or obesity treatment are at a lower risk for suicidal ideation than adults using non-GLP-1 receptor agonists, according to recent findings.

Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open.

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.

People with diabetes using a 15-day continuous glucose monitor sensor can now integrate their CGM with an automated insulin delivery system, according to a press release.

Disordered eating behaviors were reported by 42.5% of adolescents with type 1 diabetes who currently use or previously used an insulin pump, according to findings published in Diabetes Technology & Therapeutics.

Adults with type 2 diabetes who used an artificial intelligence-based app to manage their basal insulin reached their optimal dose in a shorter amount of time than adults receiving standard of care, according to a study data.

Glucagon-like peptide 1 receptor agonists were associated with a reduced risk for colorectal cancer among patients with type 2 diabetes, regardless of weight status, compared with other antidiabetics, according to research.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.